AbbVie: Renal Insufficiency, Chronic trials

The registry lists 20 Renal Insufficiency, Chronic studies with AbbVie as lead sponsor. 0 are open to participants now and 16 have results posted.

Phase 2 4Phase 3 5Phase 4 3No phase 8(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study to Evaluate Safety, Efficacy and Pharmacokinetics of Paricalcitol For Treatment of Secondary Hyperparathyroidism (SHPT) in Pediatric Participants With Stage 5 Chronic Kidney Disease (CKD)TerminatedNCT04064827Phase 3Results posted
• Post Marketing Observational Study on Paricalcitol IV Administered to Venezuelan PatientsTerminatedNCT01758289Results posted
• A Pilot Clinical Study Evaluating the Effect of Parathyroid Hormone (PTH) Lowering On Erythropoietin Consumption in Calcitriol-Resistant PatientsCompletedNCT01506947Phase 4Results posted
• Observational Program of Zemplar in Patients With End Stage Chronic Kidney Disease and Parathyroid Disorder on Hemodialysis in the Russian FederationCompletedNCT01401478Results posted
• A Study to Evaluate the Safety of Paricalcitol Capsules in Pediatric Subjects Ages 10 to 16 With Stage 5 Chronic Kidney Disease Receiving Peritoneal Dialysis or HemodialysisCompletedNCT01382212Phase 3Results posted
• Quality of Life in Greek Hemodialysis Patients Receiving Zemplar IntravenousCompletedNCT01368042Results posted
• Comparison of Efficacy and Safety of Paricalcitol Injection With Maxacalcitol Injection in Adult Japanese Chronic Kidney Disease Subjects Receiving Hemodialysis With Secondary HyperparathyroidismCompletedNCT01341782Phase 3Results posted
• Study to Assess Patient Management Practices and Quality of Life With Paricalcitol Capsules in the Treatment of Secondary Hyperparathyroidism in Stage 3-5 Chronic Kidney Disease Patients Not Yet on DialysisCompletedNCT01265992Results posted
• Evaluation of Treatment With Zemplar Capsules in the Therapy of Secondary Hyperparathyroidism (SHPT)CompletedNCT01224782Results posted
• Study to Evaluate Safety of Vitamin D Receptor Activators in Patients Ages 0 to 16 With Chronic Kidney Disease Stage 5 Receiving Peritoneal Dialysis Within Current Clinical PracticeTerminatedNCT01134315Results posted
• Long-Term Therapy Outcomes When Treating Chronic Kidney Disease (CKD) Patients With Paricalcitol in German and Austrian Clinical PracticeCompletedNCT01083849Results posted
• Study to Evaluate the Effect of Intravenous (IV) Paricalcitol (Zemplar) on Cardiac Morbidity in Patients With Chronic Kidney Disease (CKD) Stage 5 Over 2 YearsCompletedNCT01073462Results posted
• Safety and Efficacy of Paricalcitol Capsules in Decreasing Serum Parathyroid Hormone Levels in Children Aged 10-16 With Chronic Kidney Disease (CKD)CompletedNCT01020487Phase 3Results posted
• The PRIMO Study: Paricalcitol Capsules Benefits Renal Failure Induced Cardiac Morbidity in Subjects With Chronic Kidney Disease Stage 3/4CompletedNCT00497146Phase 3Results posted
• Effect of Ferrlecit® Versus Oral Iron on Iron Deficient Chronic Kidney Disease (CKD) PatientsCompletedNCT00224055Phase 4Results posted
• Effect of Ferrlecit® Versus Oral Iron on Iron Deficient Chronic Kidney Disease (CKD) Patients Receiving Erythropoietic AgentsCompletedNCT00224042Phase 4Results posted
• Reducing Residual Albuminuria in Subjects With Diabetes and Nephropathy With AtrasentanCompletedNCT01424319Phase 2
• A Prospective, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate Efficacy and Safety of Atrasentan, Including Thoracic Bioimpedance, in Type 2 Diabetic Subjects With NephropathyCompletedNCT01399580Phase 2
• Evaluate the Efficacy and Safety of Once Daily Administration of Atrasentan Tablets (Low and High) Compared to Placebo in Reducing Residual Albuminuria in Type 2 Diabetic Patients With Nephropathy Who Are Treated With the Maximum Tolerated Labeled Dose of a Renin Angiotensin System (RAS) InhibitorCompletedNCT01356849Phase 2
• A Study of Atrasentan on Reducing Albuminuria in Type 2 Diabetic Nephropathy Treated With Renin-Angiotensin System InhibitorsCompletedNCT00920764Phase 2